Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2003

View Archived Issues

New p38 inhibitors with utility in COPD

AstraZeneca describes new immunosuppressants with potential in respiratory disorders

Bayer scientists present novel bradykinin B1 antagonists for use as analgesic agents

Dopamine D2 receptor partial agonists prepared and tested at Wyeth

New modulators of vasopressin and/or oxytocin receptors covered by Sanofi-Synthelabo patent

Series of melanocortin MC4 receptor agonists in early development at Merck

Dr. Reddy's describes novel antidiabetic agents

New MRI agents designed at Bracco

NicOx reports substantial progress for 2002

New data on adefovir dipivoxil in the long-term treatment of chronic hepatitis B

Aphton presents phase III results for G17DT to foreign regulatory authority

Cardiome reviews 2002, presents outlook for 2003

Mechanisms underlying effects of zoledronic acid on prostate cancer bone metastases

AVAC for atopic dermatitis completes phase I testing in children

Ranexa NDA accepted for filing

NIAID to fund GTC clinical production of MSP-1 malaria vaccine

Oral tazarotene completes phase III studies

MVA-BN nef shows promise in HIV trial

Pennsaid approved in Italy

FDA panel recommends approval for Factive in respiratory tract infections

Argatroban meets primary endpoints in ARGIS-I study

Lercanidipine 20 mg approved in Europe

Dryvax side effects reduced by prior immunization with NYVAC or MVA

NIH licensing opportunity: gp64 pseudotyped vectors and uses thereof

Discovery of potent and selective 5-HT7 receptor antagonists

A-349821 characterized as potent, selective, orally available H3 receptor antagonist

GVAX enhances antitumor immunity in certain patients with advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...